Vanta targets U.S. peptide platform launch, estimates C$ 850,000 initial capital need

• Vanta Holdings outlined plans to launch a U.S. peptide platform built around telehealth prescribing, compounding-pharmacy fulfillment, manufacturing, and payment processing.
• The company estimated C$ 850,000 of initial capital to support launch and early-stage scaling, including inventory, clinician onboarding, commercialization, and compliance.
• The update followed a July 23-24 FDA advisory committee vote recommending six peptides for the 503A bulks list, a potential pathway for 503A compounding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vanta Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607281615ACCESSWRNAPR_____1197235) on July 28, 2026, and is solely responsible for the information contained therein.